Global Primary Antibodies Market To Reflect Impressive Growth Rate by 2028||Leading Players-Thermo F – PharmiWeb.com

Global Primary antibodies MarketIndustry Trends and Forecast to 2028 focuses on the major drivers and limitations for the key players. These research report also provides Comprehensive analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Primary antibodies market research report is a professional and in-depth study on the current state of Primary antibodies Industry. Report Carrying 350 pages,60 Figures And220 Tables in it.

This report studies the Primary antibodies market. Management consulting is the practice of assist organizations to improve their development, performance, operating primarily through the analysis of existing organizational problems and the development of plans for improvement. Organizations may draw upon the services of management consultants for a number of reasons, including gaining external (and presumably objective) advice and access to the consultants specialized expertise

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts)https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-antibodies-market

Primary antibodies market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Analysis analyses the market for growth in the above forecast timeframe at a CAGR of 7.70%. Increasing levels of investment in research and development activities will further create lucrative opportunities for market growth.

The major players covered in the primary antibodies market report are

Global Primary Antibodies Market Scope and Market Size

Primary antibodies market is segmented on the basis of type, technology, source, research area, application, end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on type, the primary antibodies market is segmented into monoclonal antibodies, and polyclonal antibodies.

On the basis of technology, the primary antibodies market is segmented into immunohistochemistry, immunofluorescence, western blotting, flow cytometry, immunoprecipitation,ELISA, and other technologies.

Based on source, primary antibodies market is segmented into mouse, rabbit, goat, and other sources.

On the basis of research area, the primary antibodies market is segmented into infectious diseases, immunology,oncology, stem cells, neurobiology, and others.

Based on application, the primary antibodies market is segmented into proteomics, drug development, and genomics.

Primary antibodies market has also been segmented based on the end user into pharmaceutical and biotechnological companies, academic and research institutes, and contract research organizations.

Grab Your Report at an Impressive 30% Discount! Please click Here @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-primary-antibodies-market

Primary Antibodies Market Country Level Analysis

Primary antibodies market is analysed and market size insights and trends are provided by country, type, technology, source, research area, application and end user as referenced above.

The countries covered in the primary antibodies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The U.S. dominates the North America primary antibodies market due to the growing number of stem cell, biomedical and cancer research along with increasing occurrences of chronic disorders in the region, while Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2021 to 2028 due to the surging levels of investment on research and development activities in the region.

Strategic Key Insights Of The Primary Antibodies Report: Production Analysis Production of the Patient Handling Equipment is analyzed with respect to different regions, types and applications. Here, price analysis of various Primary antibodies Market key players is also covered. Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the Primary antibodies Market. Another major aspect, price, which plays an important part in the revenue generation, is also assessed in this section for the various regions. Supply and Consumption In continuation of sales, this section studies supply and consumption for the Primary antibodies Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.

Competitors In this section, various Primary antibodies industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue. Analytical Tools The Primary antibodies Market report consists the precisely studied and evaluated information of the key players and their market scope using several analytical tools, including SWOT analysis, Porters five forces analysis, investment return analysis, and feasibility study. These tools have been used to efficiently study the growth of the major industry participants. The 360-degree Primary antibodies overview based on a global and regional level. Market share, value, volume, and production capacity is analyzed on global, regional and country level. And a complete and useful guide for new market aspirants Facilitates decision making in view of noteworthy and gauging information also the drivers and limitations available of the market.

For More Insights Get FREE Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-primary-antibodies-market

Drivers:Global Primary Antibodies Market

Increasing levels of investment in research and development activities will further create lucrative opportunities for market growth.

Increasing number of stem cell and neurobiology research, rising academicresearchand industry collaborations, growing availability of the technologically advanced products, increasing focus on the biomarker discovery are some of the major as well as impactful factors which will likely to augment the growth of the primary antibodies market in the projected timeframe of 2021-2028.

On the other hand, increasing number of applications from emerging economies along with rising demand forpersonalized medicinesand protein therapeutics which will further contribute by generating immense opportunities that will led to the growth of the primary antibodies market in the above mentioned projected timeframe.

Customization Available :Global Primary Antibodies Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingsopan.gedam@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research US: +1 888 387 2818 UK: +44 208 089 1725 Hong Kong: +852 8192 7475 Email: Corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Visit link:
Global Primary Antibodies Market To Reflect Impressive Growth Rate by 2028||Leading Players-Thermo F - PharmiWeb.com

US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use – USA TODAY

The FDA has authorized Moderna's COVID-19 vaccine for emergency use in the U.S. The first shots of the vaccine are expected to be given Monday. USA TODAY

CAMBRIDGE, Mass. Americans will soon have access to a second COVID-19 vaccine.

Stephen Hahn, commissioner of the U.S. Food and Drug Administration, granted emergency authorization Fridayto a vaccine made by Moderna,a week after giving similar clearance to one made by Pfizer and its German collaborator, BioNTech.

His is "authorizing" rather than approving the vaccine, because longer-term research is needed to meet the full standards for approval, which officials don't want to wait for during the public health emergency.

The speedy path to authorization was possible because the agencycut through regulatory red tape,Hahnsaid at a Friday night press conference. "We worked quickly based onthe urgency of this global pandemic ... we have not cut corners."

The announcementmakesthe U.S.the first country to authorize two COVID-19 vaccines that demonstrate "clear and compelling efficacy, Dr.Peter Marks director of the Center for Biologics Evaluation and Research at the FDA said during the press conference.Marks said it isanother milestone as we work to end the COVID-19 pandemic.

The move comes a day afterthe U.S. reported its 17 millionth case of COVID-19and an independent advisory committee reviewed data from human trials of Moderna's mRNA-1273 vaccine, deciding its benefits outweighed its risks. The vaccine, according to a trial that included 30,000 volunteers,protected more than94% of recipients from active disease, without causing major safety concerns.

Trucks will begin moving the vaccine this weekend, with the first of 5.9 million already manufactured Moderna shots expected to be given on Monday.

Your vaccine questions, answered:I had COVID, should I still get vaccinated? What are the side effects? What are its 'ingredients?'

In this special edition episode of States of America, experts answer the biggest questions Americans have about the vaccine, side effects, how it's getting to you and more. USA TODAY

It's a triumphant moment for the 10-year-old Cambridge, Massachusetts, biotech companythat until nowhad never brought a product to market.

Now, both its vaccine and the one byPfizer-BioNTecharepoised to change the course of the worst pandemic in a century.

The virus that causes COVID-19 hasswept the world and particularly devastated the United States, which accounts for 4% of the world's populationbut nearly 23%of its COVID-19 cases and 19%of its deaths.

During the current winter surge, anAmerican is reported dead about every 34 seconds from the virus, and 150 are diagnosed every minute.

But it will take time to roll out vaccine across the country and the world, achieving the 70% protection from both vaccination and natural disease that experts say will be needed to stop widespread infections.

In this file photo taken on November 18, 2020 shows a syringe and a bottle reading "Vaccine Covid-19" next to the Moderna biotech company logo.(Photo: JOEL SAGET, AFP via Getty Images)

Moderna, which developed its vaccine in collaboration with government scientists,says it will be able to deliver 20 million doses of its vaccine by the end of December. Another 80 million will be available in the first few months of 2021, under a contract signed in Augustthat brought the U.S. government's direct financial backing of the companyto $2.5 billion.

"It is through the dedicated efforts of our federal scientists and their collaborators at Moderna and in academia, the clinical staff who conducted the vaccine's rigorous clinical trials, and the tens of thousands of study participants who selflessly rolled up their sleeves, that another safe and highly effective vaccine to protect against COVID-19 will soon be rolled out to the American public," Dr. Francis Collins, director of the National Institutes of Health, said Friday.

Just last week, the government closed a deal for a second 100 million doses to be delivered in the second quarter of next year, bringing taxpayers' total investment in mRNA-1273 up to$4.1 billion.

Another candidate vaccine, from Johnson & Johnson, fully enrolled its large-scale humantrial Thursdayand expects to report its first safety and effectiveness data in January.

A fourth, created by AstraZeneca and Oxford University, is a few weeks behind, and a fifth candidate, by vaccine developer Novavax ofGaithersburg, Maryland, is expected to begin its major U.S. trial shortly.

If all or most of these come through, there shouldbe plenty of vaccine by the endof next summer to cover every American who wants one.

"It's just incredible science and human achievement,"said Dr. Steven Joffe, a professor of medical ethics and health policyat the Perelman School of Medicine at the University of Pennsylvania."Not just the science that went into the vaccines, but the organizational effort to pull off those trials it's marvelous."

Although Moderna moved extremely fast, winning authorization just 11 months after beginning work on mRNA-1273, ithas been developing the technology behind its vaccinefor a decade.

The company was founded in 2010 on the banks of the Charles River, a short walkfrom the Massachusetts Institute of Technology, where one of its founders was a faculty member,and another a graduate and board member.

That MIT gradand board of trustees member, venture capitalist Noubar Afeyan,said he was intrigued at the time by the idea of making drugs inside the human body.

Messenger RNA, which the body uses to translate the DNA code into the proteins that do all the body's work, seemed like the right tool to address a whole host of medical problems, he said.

Operation Warp Speed has helped Moderna move faster in vaccine development.(Photo: JOSEPH PREZIOSO/AFP via Getty Images)

Afeyan saidhe likes to start companies with big ideas that seem like science fictionand then "take the fiction out" by finding the science to make it real.

Moderna was initially namedLS18 to indicate it was the 18th life sciences company Afeyan had started. (He's lost track of whether his latest company is LS79 or LS80, he said.) The idea was seeded by a stem cell scientist at nearby Harvard University, Derrick Rossi, who was trying to commercialize his research using the body's most versatile cells to make medicines.

Afeyan said it was a provocative concept. But by May of the following year, when the company was officially launched as Moderna, they had dropped the idea of using stem cells, which Afeyan said were too unstable in the body, and focused instead on messenger RNA (hence the name ModeRNA).

Messenger or mRNA is the body's own delivery system, taking "messages" from the DNA code in the cell's nucleus to a protein manufacturing center.

Where's the COVID-19 vaccine? Who's been vaccinated?Here's how we'll know.

These proteins direct every activity of life, so figuringout how to make them on demand could help people who suffer severe diseases because their bodies make faulty proteinsas with sickle cell disease, cystic fibrosis and myriad rare diseases. Such proteins could alsoprime the immune system to target cancer cells, or infectious diseases.

Afeyan and his collaborators wanted to tackle this whole range of medical challenges.

But first, they needed a CEO to run the company.

Afeyan said he had been negotiating with a French entrepreneur who was, like him, a biomedical engineer. ButStphane Bancel wasn't sure he wanted to leave a stable job as CEO of an established diagnostics company for the risk of a startup with a never-before-tried idea.

Bancel was walking home across the Longfellow Bridge from Cambridge to Boston one winter night, when Afeyan called and turned on the hard sell.

Afeyan said he would never have a bigger idea to offer Bancel. If this becomes the next Genentech, "you're going to hate yourself" for not being involved, Afeyan told him, referring to the South San Francisco company that launched the entire biotechnology industry with its birth in 1976.

Later that year, Bancel signed on to run Modernaand continues to lead the company, which has now made several founders and its CEO into billionaires.

Moderna IPO(Photo: Flagship Pioneering)

The earliest seeds of Moderna

There werea few key scientific advances that led mRNA to where it is today.

Onecame from another Moderna co-founder, Robert Langer, a professor at MIT and a serial entrepreneur.

Early in his career, Langer, who had recently earned his doctorate in chemical engineering from MIT, was struggling to find a job. He didn't want to work in the oil industry, though he'd gotten 20 job offers, including fourfrom Exxon alone.

After months of searching, Dr. Judah Folkman, a passionate doctor at what is now called Boston Children's Hospital finally took a chance on him. Folkman believed he could cure cancer by cutting off the blood supply to tumorsbut he couldn't figure out how to slowly release drugs to work effectively.

Nevermind the political messenger: When it comes to COVID-19 guidance, trust the message, experts say

Langer spent years developinga way to encapsulatenucleic acids the same building blocks as in mRNA vaccines into tiny particles that could make their way into cells.

"At first people didn't think it was possible," Langer said. He published a 1976 paper showing it could be donebut still, it was a slog to get people to believe in its potential.

"After that paper came out, I must have had 10 years of people rejecting grants" to support the work, he said. (His work with Folkman provided the underlying science for the drug Avastin, which earned $7 billion in sales in 2019 and is used to treat many types of cancer as well as wet age-related macular degeneration, the leading cause of blindness in older adults.)

Langer and others made additional improvements over the years, includingadding polyethylene glycol to the surface of particles, which enabled them to survive in the body for longer. That's one of the key ingredients of Moderna and Pfizer-BioNTech's vaccines.

A subject receives a shot in the first-stage safety trial of a potential vaccine by Moderna for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle on March 16.(Photo: Ted S. Warren, AP)

In 2010, when Langer was one of the world's best knownbioengineers and a leader in the field of drug delivery, Rossi came to see him with a scientific insight he hoped would be the basis for starting a company. Langer introduced him to Afeyan, and the idea for LS18was born.

By the following year,Rossi moved on and the core group includedLanger, Afeyan, Dr. Kenneth Chien, a prominent cardiologist and researcher, andTimothy Springer, an immunologist at Harvard Medical School.

The four met once a week tobrainstorm, while a handful of scientists at Afeyan's Flagship Pioneering advanced their ideas in the lab.

Moderna's first real home wasan underwhelming office half basement, half ground floor just a few blocks away.

The vision from its earliest days, Langer said, was to build a "platform" that could be used as the basis for drugs, vaccinesand even tissue engineering another field he had helped pioneer.

Some Americans aren't in a rush to get a COVID-19 vaccine: Experts understand, but say there's no need to wait.

For several years, Moderna has been collaboratingon vaccine development withscientists at the National Institute of Allergy and Infectious Diseases, the agency led by Dr. Anthony Fauci.

By the end of 2018 when Moderna went public,it was the biggest initial public offering ever for a biotech company, though shares fell 19% that first day as investors worried it was overpriced.

A year later the company was testing 20 different mRNA's in humans five or six times more research programs than the typical biotech.

That was enough, said Nina Deka, a senior research analyst at ROBO Global, for her fund to decide to make Moderna one of the 85 companies included in its portfolio of health care technology and innovation stocks.

Moderna had recently announced plans to develop a COVID-19 vaccine when ROBO Global decided to invest.

"Not because of what they did this year, but what they've done since the start of the company," Deka said.

With two mRNA vaccines under development, ROBO Global expected that even if Moderna's vaccine didn't succeed, the technology would advance, buoying everyone in the industry.

"It's not just vaccines. It's also cancer. It's also orphan drugs" for rare diseases, she said.

The company had just built a brand new production facility in the Boston suburb of Norwood, and it was using advanced artificial intelligence to direct its research, which ROBO Global appreciated,Deka said.

Plus, it was breaking speed records with its candidate COVID-19 vaccine.

"The next question is," Deka said,"if they can do this quickly, what else can they do?"

Contact Karen Weintraub at kweintraub@usatoday.com

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/news/health/2020/12/18/moderna-covid-19-vaccine-authorized-fda-emergency-use/3941886001/

Excerpt from:
US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use - USA TODAY

Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -…

STOCKHOLM, Dec. 16, 2020 /PRNewswire/ -- Diamyd Medical and the Critical Path Institute (C-Path) are proud to announce their collaboration to significantly improve the scientific community's insight into type 1 diabetes (T1D) through Diamyd Medical's contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Measures Initiative (TOMI) T1D integrated database.

The Phase III trial evaluated the use of the diabetes vaccine Diamyd, an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. The Data Contribution Agreement between Diamyd Medical and C-Path will allow for this unique set of fully anonymized clinical trial data to be integrated into an ever-growing list of committed trial data sets within the TOMI-T1D project.

TOMI-T1D is an international partnership between academia, the pharmaceutical industry and nonprofit organizations. It is funded by the world's leading charities dedicated to diabetes research, JDRF, and Diabetes UK, guided by both organizations' strong commitment to facilitate deep interrogation of consolidated community-wide trial data as a means to accelerate clinical research and therapeutic development for T1D. TOMI-T1D aims to create a clinical trial simulation tool (CTST) with large and diverse clinical datasets from the T1D community. The project also seeks to engage the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to identify opportunities for regulatory endorsement of such drug development tools.

The Diamyd Medical data includes relevant information about disease progression, drug effects and clinical trial design. Contribution of these robust data sets from industry led trials is critical to TOMI-T1D's work in developing innovative and quantitative tools that can facilitate clinical development efforts and be endorsed by regulators for future use by the pharmaceutical industry to optimize the design of future clinical trials.

"Progress towards the establishment of approved therapies for people with T1D is critically reliant on participation from our partners in industry with their data", said Simi Ahmed and Elizabeth Robertson, on behalf of the charity partnership.

"This is indeed a right step in that direction", said Colin Dayan, lead PI at Cardiff University.

"We are thrilled that Diamyd Medical is taking a leading role and championing precompetitive collaborations advancing type 1 diabetes regulatory science solutions", said Inish O'Doherty Executive Director at C-Path. "Their data will help in the construction and evaluation of a clinical trial simulation tool to assist in the development of novel therapies for type 1 diabetes patients".

"We are very honored to be part of this important collaboration -involving key stakeholders within the type 1 diabetes landscape, said Ulf Hannelius, President & CEO of Diamyd Medical. "As we are moving into an era of precision medicine in type 1 diabetes, we can expect to see significant therapeutic advances, and access to high quality data will be integral to maximizing these efforts".

To learn more about the TOMI-T1D project visit: https://c-path.org/programs/tomi-t1d/

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path US is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.

About JDRF

JDRF's mission is to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact and uniting on a national stage to pool resources, passion and energy. We collaborate with academic institutions, policymakers and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

About Diabetes UK

1. Diabetes UK's aim is creating a world where diabetes can do no harm. Diabetes is the most devastating and fastest growing health crisis of our time, affecting more people than any other serious health condition in the UK - more than dementia and cancer combined. There is currently no known cure for any type of diabetes. With the right treatment, knowledge and support people living with diabetes can lead a long, full and healthy life. For more information about diabetes and the charity's work, visit http://www.diabetes.org.uk

2. Diabetes is a condition where there is too much glucose in the blood because the body cannot use it properly. If not managed well, both type 1 and type 2 diabetes can lead to devastating complications. Diabetes is one of the leading causes of preventable sight loss in people of working age in the UK and is a major cause of lower limb amputation, kidney failure and stroke.

3. People with type 1 diabetes cannot produce insulin. About 10 per cent of people with diabetes have type 1. No one knows exactly what causes it, but it's not to do with being overweight and it isn't currently preventable. It's the most common type of diabetes in children and young adults, starting suddenly and getting worse quickly. Type 1 diabetes is treated by daily insulin doses - taken either by injections or via an insulin pump. It is also recommended to follow a healthy diet and take regular physical activity.

4. People with type 2 diabetes don't produce enough insulin or the insulin they produce doesn't work properly (known as insulin resistance). Around 90 per cent of people with diabetes have type 2. They might get type 2 diabetes because of their family history, age and ethnic background puts them at increased risk. They are also more likely to get type 2 diabetes if they are overweight. It starts gradually, usually later in life, and it can be years before they realise they have it. Type 2 diabetes is treated with a healthy diet and increased physical activity. In addition, tablets and/or insulin can be required.

For more information on reporting on diabetes, download our journalists' guide: Diabetes in the News: A Guide for Journalists on Reporting on Diabetes (PDF, 3MB).

About Diamyd Medical

Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale metastudy as well as in the Company's European Phase IIb trial DIAGNODE-2, where the diabetes vaccine is administered directly into a lymph node in children and young adults with newly diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd. Diamyd Medical also develops the GABA-based investigational drug Remygen as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

CONTACT:

For further information, please contact:

Ulf Hannelius, President and CEO

Phone: +46 736 35 42 41

E-mail: ulf.hannelius@diamyd.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-and-critical-path-institute-announce-data-sharing-collaboration-to-develop-advanced-d,c3255392

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/diamyd-medical-and-critical-path-institute-announce-data-sharing-collaboration-to-develop-advanced-drug-development-tools-in-type-1-diabetes-301193791.html

SOURCE Diamyd Medical AB

Company Codes: Frankfurt:DMN, ISIN:SE0005162880, Munich:DMN, Stockholm:DMYD, Stockholm:DMYD-B.ST

View original post here:
Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -...

Skandalaris LEAP winners announced | WashU Fuse | Washington University in St. Louis – Washington University in St. Louis Newsroom

Its been a busy and exciting time for our friends at Skandalaris Center: This week they announced winners of both the Skandalaris Venture Competition (SVC) and Fall 2020 LEAP Cycle.

The Skandalaris Centers Fall 2020 LEAP Cycle has ended and a new set of translational research projects have been funded. LEAP is an asset-development program and gap fund designed to provide intellectual and financial capital to WashU-affiliated translational projects.

A panel of industry experts and community partners evaluated 22 projects based on three criteria:

Seven teams were selected to receive LEAP funds and accelerate their projects towards partnering and launching:

AIR Seal allows for quick, easy ventilation of COVID-19 patients through a laryngeal mask airway (LMA) that is dynamically sealed to block viral aerosol transmission.

TEAM:Vivian Lee, graduate student, Doctor of Medicine, School of Medicine Mohamed Zayed, vascular surgeon/assistant professor of surgery, School of Medicine Chase Hartquist, undergraduate/graduate student, Mechanical Engineering, McKelvey School of Engineering Halle Lowe, undergraduate/graduate student, Mechanical Engineering, McKelvey School of Engineering Vinay Chandrasekaran, undergraduate student, Computer Science, McKelvey School of Engineering

The first single-use, disposable device capable of performing continuous bedside pressure-monitoring, preventing pressure-ulcer development/progression, and reducing hospital liability and spend related to pressure-ulcer care.

TEAM: Justin Sacks, Shoenberg Professor; chief of Division of Plastic and Reconstructive Surgery, School of Medicine

EnhanceAR-Seq lets the clinician personalize prostate cancer treatment through a blood-based liquid biopsy to improve patient survival.

TEAM: Aadel Chaudhuri, assistant professor of Radiation Oncology, School of Medicine Christopher Maher, associate professor, Oncology Division, Stem Cell Biology, School of Medicine Russell Pachynski, assistant professor, Oncology Division, Molecular Oncology, School of Medicine

FLAAM is a new approach to 3D printing metals that is capable of fabricating novel components composed of many highly-desired materials not accessible in existing 3D printing processes, including ultra-high temperature materials, materials with locally tailored properties, and entirely new metal alloys.

TEAM:Richard Axelbaum, Stifel and Quinette Jens Professor of Environmental Engineering Science, McKelvey School of Engineering Phillip Irace, PhD candidate, McKelvey School of Engineering Kathy Flores, professor, Mechanical Engineering & Material Science, McKelvey School of Engineering Daniel Miracle, senior scientist, Aire Force Research Lab

A sensitive, radiological imaging tool (RadioCF-PET) to detect kidney damage in its earliest stages to improve and facilitate personalized therapies to prevent or slow the development of kidney disease.

TEAM:Edwin Baldelomar, postdoctoral research fellow, Institute of Clinical Translational Sciences (ICTS) Kevin Bennett, associate professor of Radiology, School of Medicine Jennifer Charlton, pediatric nephrologist & associate professor, University of Virginia

Aims to license the first safe and effective virus that specifically targets cancer stem cells, the most treatment-resistant cells in brain tumors.

TEAM: Milan Chheda, assistant professor of Medicine and Neurology, School of Medicine Michael Diamond, The Herbert S. Gasser Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology, School of Medicine

The LEAP program is helpful beyond the funding. We benefited from the process of writing the proposal, incorporating market research, andmost importantlyclearly defining what needs to be done to forge a successful licensing partnership.

SonoBiopsy provides molecular diagnoses of brain diseases without surgery.

TEAM: Hong Chen, assistant professor, Biomedical Engineering, McKelvey School of Engineering Chris Pacia, graduate student, PhD, Biomedical Engineering, McKelvey School of Engineering Lu Xu, graduate student, PhD, Biomedical Engineering, McKelvey School of Engineering

LEAP is supported by Washington University in St. Louis Institute of Clinical and Translational Sciences, Siteman Cancer Center, Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship, Center for Drug Discovery, and Office of Technology Management.

Learn more about LEAP.

Read more:
Skandalaris LEAP winners announced | WashU Fuse | Washington University in St. Louis - Washington University in St. Louis Newsroom

Glycostem and Ghent University sign license agreement on NK cell therapy technology – PRNewswire

OSS, Netherlands, Dec. 17, 2020 /PRNewswire/ --Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, and Ghent University (UGent) have signed a license agreement for an innovative NK cell production technology. Ultimately, this agreement will bring significant benefit to targeted treatment of patients suffering from cancer. The agreement not only opens up new opportunities for development of NK-antibody combination therapies but also has significant positive impact on the production time of Glycostem's lead product oNKord and its second (CAR-NK) and third (TCR-NK) generation therapies viveNKTM.

"This license agreement offers new opportunities for more targeted treatment of cancer patients. By using UGent's technology we are able to increase the expression of CD16 receptors resulting in an increase of the NK-cell's activity and its antibody binding properties. When a patient's immunity is weak, administering NK-cells will boost the patient's immune system and increase the antibody's therapeutic effectiveness," explains Troels Jordansen, CEO at Glycostem.

Glycostem's NK-cell based therapies are manufactured in its in-house GMP licensed facility. "Ghent University's technology has the potential to almost halve the time needed for NK cell progenitor cells to differentiate into fully functional NK-cells. By incorporating this in our processes both our manufacturing time and cost-effectiveness will be affected very positively without negative effect on the potency of the NK cells. This is an important part of paving the way for further upscaling the production of our NK-cells," says Troels Jordansen.

"We are glad to see our research translated to a clinical setting as it is based on many years of fundamental research into NK cell biology," tells Prof. Georges Leclercq, head of the UGent research team and group leader in the Cancer Research Institute Ghent (CRIG). "We hope that with this collaboration, we can positively impact the lives of many patient's affected by difficult to treat cancers."

Dr. Dominic De Groote (UGent Business Development) further explains: "This partnership is the result of continuing efforts by Ghent University and Ghent University Hospital to become a leading academic and clinical center for cell-based therapies. This technology is part of our growing portfolio of oncology and Advanced Therapy Medicinal Products (ATMP) related assets that we are actively developing from the bench to the bedside through our translational platforms."

Taking cellular immunotherapy to the next level

Glycostem is focused on developing first, second and third generation cancer treatments based on NK-cells. This licensing deal will affect Glycostem's full portfolio. After a successful phase I study Glycostem initiated a first-of-its-kind pivotal trial in acute myeloid leukemia (AML) with in-house manufactured nonmodified NK cells (oNKord). Over the coming months, AML patients will receive this form of treatment as part of a phase I-IIa trial. A pivotal phase IIa trial for Multiple Myeloma (MM) patients is expected to start second half of 2021. This makes Glycostem one of the frontrunners in this promising field of cellular immunotherapy.

About Glycostem

Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company, develops allogeneic cellular immunotherapy to treat several types of cancer. By harnessing the power of stem cell-derived Natural Killer (NK) cells, Glycostem's products are a safe alternative to CAR-T-cells. Glycostem's lead product, oNKord, is manufactured from allogeneic raw material and is available off-the shelf. Thanks to its nine patent families, longstanding technical expertise and resources, as well as 'Orphan Drug Designation', Glycostem has secured a leadership position in the global NK-cell market.

oNKord is produced in a closed system (uNiKTM) in Glycostem's state-of-the-art and GMP (Good Manufacturing Practice) licensed production facility in the Netherlands, from which it can be distributed globally. The production technology includes ex vivo generation of high numbers of NK-cells with a high degree of purity for clinical applications. oNKord successfully passed phase I clinical trial (elderly and frail AML - Acute Myeloid Leukemia - patients), providing solid safety data and strong indication of clinical activity, including response on MRD (Minimal Residual Disease). Results indicate that oNKord may be safely infused in AML patients.

Glycostem is furthermore developing a range of CAR-NK and TCR-NK products in-house and in cooperation with global partners.

Glycostem Therapeutics BV http://www.glycostem.com

Foot note: "oNKord" is a registered trademark of Glycostem in the US and in Europe. Trademark registrations of "viveNK" and "uNiK" are pending.

About Ghent University

Ghent University (UGent) is a major Belgian university located in the heart of Europe. Our organization is dedicated to research and innovation with over 5,500 researchers active in a wide area of life, physical and social sciences. Strong partnerships with the Ghent University Hospital (1000+ beds), VIB, IMEC and global leaders in academia and pharma/biotech industry thrive life science innovation at our university and is part of the thriving Belgian biotech region. Our translational platforms such as CRIG (focus on cancer) and GATE (focus on advanced therapy medicinal products) facilitate to bring science to the patient.

Prof. Georges Leclercq has a longstanding and internationally recognized expertise in differentiation and function of NK cells. The recent focus of his research group is to reveal the role of several transcription factors in the differentiation of human hematopoietic stem cells into mature NK cells, and in the maintenance and function of these mature NK cells. The ultimate aim is to attribute to improved NK-based cancer immunotherapy.

Cancer Research Institute Ghent http://www.crig.ugent.be

SOURCE Glycostem

Visit link:
Glycostem and Ghent University sign license agreement on NK cell therapy technology - PRNewswire

Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke – PRNewswire

PHOENIX, Dec. 16, 2020 /PRNewswire/ --Creative Medical Technology Holdings Inc., (OTC CELZ) announced today positive preclinical data supporting the utilization of its ImmCelz cell based immunotherapy for treatment of stroke. In an animal model of ischemia stroke, the middle cerebral artery ligation model, administration of ImmCelz resulted in 34% reduction in infarct volume, whereas control bone marrow mesenchymal stem cells reduced infarct volume by 21%. Additionally, improvements in functional recovery where observed using the Rotarod test. At 28 days after induction of stroke the animals receiving ImmCelz had superior running time (92% of non-stroke controls) compared to animals which received bone marrow mesenchymal stem cells (73% of non-stroke control). Animals that received saline had a running time that was 50% of non-stroke controls.

"The regenerative potential of immune cells that have been programmed by stem cells is a fascinating and novel area of research." Said Dr. Amit Patel, coinventor of ImmCelz, and board member of the Company. "Conceptual advantages of using reprogrammed T cells include higher migratory ability due to smaller size, as well as ability to replicate and potentially form "regenerative memory cells."

"This data, which is covered by our previous filed patents, such as no. 15/987739, Generation of autologous immune modulatory cells for treatment of neurological conditions, demonstrate that immune modulation via this stem cell based method may be a novel and superior way of addressing the $30 billion dollar market for stroke therapeutics1." Said Dr. Thomas Ichim, coinventor of the patent and Chief Scientific Officer of the Company. "The fact that this technology, which has priority back to 2017, is demonstrating such stunning results, motivates us to consider filing an Investigational New Drug Application for use in stroke."

Creative Medical Technology Holdings possesses numerous issued patents in the area of cellular therapy including patent no. 10,842,815 covering use of T regulatory cells for spinal disc regeneration, patent no. 9,598,673 covering stem cell therapy for disc regeneration, patent no. 10,792,310 covering regeneration of ovaries using endothelial progenitor cells and mesenchymal stem cells, patent no. 8,372,797 covering use of stem cells for erectile dysfunction, and patent no. 7,569,385 licensed from the University of California covering a novel stem cell type.

"While stroke historically has been a major area of unmet medical need, the rise in stroke cases , as well as the fact that younger people are increasingly falling victim to stroke, strongly motivates us to accelerate our developmental programs and to continue to explore participation of Big Pharma in this space." Said Timothy Warbington, President and CEO of the Company. "We are eager to replicate the existing experiments start compiling the dossier needed to take ImmCelz into humans using the Investigational New Drug Application (IND) route through the FDA."

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visitwww.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atwww.sec.gov.

Timothy Warbington, CEO [emailprotected] CreativeMedicalHealth.com

Creativemedicaltechnology.com http://www.StemSpine.com http://www.Caverstem.com http://www.Femcelz.com

1Stroke Management Market Size Forecasts 2026 | Statistics Report (gminsights.com)

SOURCE Creative Medical Technology Holdings, Inc.

Home

Follow this link:
Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire

Creative Medical Technology Stock Price Increased 80.77%: Why It Happened – Pulse 2.0

The stock price of Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) a company that engages in stem cell research and developing applications to treat male sexual dysfunction and related issues increased by 80.77% yesterday as it went from $0.0026 to $0.0047 per share. One of the biggest triggers for the stock price increase is an announcement about the company announcing the successful application of ImmCelz immunotherapy for treatment of stroke.

In an animal model of ischemia stroke, the middle cerebral artery ligation model, administration of ImmCelz resulted in 34% reduction in infarct volume, whereas control bone marrow mesenchymal stem cells reduced infarct volume by 21%. And there were improvements in functional recovery were observed using the Rotarod test.

At 28 days after induction of stroke the animals receiving ImmCelz had superior running time (92% of non-stroke controls) compared to animals that received bone marrow mesenchymal stem cells (73% of non-stroke control). And animals that received saline had a running time that was 50% of non-stroke controls.

KEY QUOTES:

The regenerative potential of immune cells that have been programmed by stem cells is a fascinating and novel area of research. Conceptual advantages of using reprogrammed T cells include higher migratory ability due to smaller size, as well as ability to replicate and potentially formregenerative memory cells.

Dr.Amit Patel, coinventor of ImmCelz

This data, which is covered by our previous filed patents, such as no. 15/987739,Generation of autologous immune modulatory cells for treatment of neurological conditions, demonstrate that immune modulation via this stem cell based method may be a novel and superior way of addressing the$30 billion dollarmarket for stroke therapeutics. The fact that this technology, which has priority back to 2017, is demonstrating such stunning results, motivates us to consider filing an Investigational New Drug Application for use in stroke.

Dr.Thomas Ichim, coinventor of the patent and Chief Scientific Officer of Creative Medical Technology

While stroke historically has been a major area of unmet medical need, the rise in stroke cases , as well as the fact that younger people are increasingly falling victim to stroke, strongly motivates us to accelerate our developmental programs and to continue to explore participation of Big Pharma in this space. We are eager to replicate the existing experiments start compiling the dossier needed to take ImmCelz into humans using the Investigational New Drug Application (IND) route through the FDA.

Timothy Warbington, President and CEO of Creative Medical Technology

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Read the rest here:
Creative Medical Technology Stock Price Increased 80.77%: Why It Happened - Pulse 2.0

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV – GlobeNewswire

December 14, 2020 08:00 ET | Source: CRISPR Therapeutics AG

-Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide-

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV.

While we have demonstrated the promise of CRISPR/Cas9 gene editing ex vivo in sickle cell disease and beta thalassemia, an in vivo approach to editing hematopoietic stem cells could allow the transformative benefit of CRISPR/Cas9 to reach a broader array of patients, including those in low resource settings that lack sufficient infrastructure for stem cell transplantation, said Tony Ho, M.D., Executive Vice President and Head of Research & Development at CRISPR Therapeutics. We look forward to working on new therapies that could contribute to the global effort to reduce the burden of HIV.

The grant builds upon CRISPR Therapeutics proprietary CRISPR/Cas9 gene editing technology and expertise in editing hematopoietic stem cells and contributes to efforts to accelerate transformative medicines for global health.

About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking Statement This press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Ho in this press release, as well as regarding CRISPR Therapeutics expectations about any or all of the following: (i) the expected benefits of CRISPR Therapeutics research funded by the Bill & Melinda Gates Foundation and (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be favorable and predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics product candidates; potential impacts due to the coronavirus pandemic, such as the timing and progress of preclinical studies; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR THERAPEUTICS word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.com

Media Contact: Rachel Eides WCG on behalf of CRISPR +1-617-337-4167 reides@wcgworld.com

See the original post:
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - GlobeNewswire

EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan – Business Wire

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of the US Subsidiary, and Kehua Fan, M.D., as Head of Business Development. Both will report to Dr. Dong Wei, CEO of EdiGene.

Our company and R&D portfolio are entering into an exciting phase, as evidenced by the recent close of Series B financing and submission of the first gene editing product IND in China, said Dong Wei, Ph.D.CEO of EdiGene, Translating cutting-edge gene editing technologies into innovative solutions for patients requires deep internal R&D expertise as well as strong external partnerships. We are delighted to have Dr. Zhang and Dr. Fan join us at this significant stage of growth. Their extensive experience and proven track record in advancing innovative therapies, in addition to strong leadership skills, will help us to strengthen our portfolio and accelerate technology translation to help patients in need.

Dr. Zhang has around 20 years of experience in research and drug development in both industry and academia in the US. Prior to joining EdiGene, he was Vice President of KLUS Pharma and focused on cell therapy and new technologies. Before that, he was Director of Development at Cobalt Biomedicine leading CAR-T and other cell/gene therapy programs, and R&D Director at OvaScience developing stem cell-based products. Prior to that, he held various oncology research and development positions at Merrimack Pharmaceuticals and Archemix. Dr. Zhang completed his postdoctoral fellowship at Harvard Medical School/Boston Childrens Hospital. He received his B.S. degree from Henan Normal University, M.S. degree from Chinese Academy of Sciences and Ph.D. from University of New Hampshire.

Dr. Kehua Fan has over 15 years of Business Development, Clinical Development of innovative drugs and other healthcare industry experience with MNCs and biotech companies. Before EdiGene, she served as Head of Strategy and Partnership at Junshi Biosciences, in charge of pipeline development strategy focus on oncology, autoimmune and metabolic diseases along with external partnership. Before that, she held positions in business development, clinical development strategy and operation on various therapeutic areas at Quintiles, GSK, Sanofi and Pfizer. She started her career as a General Surgeon at Zhongshan Hospital of Chongqing. She received a masters degree in Cardiovascular Pharmacology from West China Medical Center of Sichuan University and a bachelors degree in Clinical Medicine from Soochow University.

About EdiGene, Inc EdiGene is a biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer. The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies. Founded in 2015, EdiGene is headquartered in Beijing, with subsidiaries in Guangzhou, China and Cambridge, Massachusetts, USA. More information can be found at http://www.edigene.com.

See the article here:
EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan - Business Wire

3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,…

December 11, 2020 08:41 ET | Source: ReportLinker

New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts, 2020-2030" - https://www.reportlinker.com/p05995354/?utm_source=GNW However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research. This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases. Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

SCOPE OF THE REPORT The 3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030 report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes: An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables. A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence. A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence. A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence. An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used. Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook. An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products. An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations. An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis. An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods. Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players: Brigitte Angres (Co-founder, Cellendes) Bill Anderson (President and CEO, Synthecon) Anonymous (President and CEO, Anonymous) Anonymous (Co-founder and Vice President, Anonymous) Scott Brush (Vice President, BRTI Life Sciences) Malcolm Wilkinson (Managing Director, Kirkstall) Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel) Tanya Yankelevich (Director, Xylyx Bio) Jens Kelm (Chief Scientific Officer, InSphero) Walter Tinganelli (Group Leader, GSI) Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED Who are the leading industry players engaged in the development of 3D cell culture products? What are the most popular 3D cell culture products? What are the different applications for which 3D cell culture products are currently being developed? What are the key factors that are likely to influence the evolution of this market? What is the trend of capital investments in the 3D cell culture systems market? Which partnership models are commonly adopted by stakeholders in this industry? How is the COVID-19 pandemic likely to impact the 3D cell culture systems market? How is the current and future opportunity likely to be distributed across key market segments? What are the anticipated future trends related to 3D cell culture systems market?

CHAPTER OUTLINES Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term. Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis.

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions) Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report. Read the full report: https://www.reportlinker.com/p05995354/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Originally posted here:
3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,...